Brief: FDA Grants Orphan Drug Designation Status To NeoImmuneTech's NT-I7 For Advanced Pancreatic Cancer Treatment
30/01/2024 11:51
Jan 30 (Reuters) - Neoimmunetech Inc 950220.KQ :
* FDA GRANTS ORPHAN DRUG DESIGNATION (ODD) STATUS TO
NEOIMMUNETECH'S NT-I7 FOR ADVANCED PANCREATIC CANCER TREATMENT
Source text for Eikon: ID:nPn9VNd6Wa
Further company coverage: 950220.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neoimmunetech
See all newsBrief: Emmaus Life Sciences Enters License And Distribution Agreement With Neoimmunetech
Brief: Neoimmunetech To Conduct Capital Increase Of 65 Billion Won For Operational Funds
Brief: FDA Grants Orphan Drug Designation Status To NeoImmuneTech's NT-I7 For Advanced Pancreatic Cancer Treatment
Brief: FDA Grants Orphan Drug Tag to NeoImmuneTech's Acute Radiation Syndrome Treatment
Brief: Neoimmunetech Presents Phase 1 Study Data At Society For Neuro-Oncology Annual Meeting